IL6 and systemic-onset juvenile idiopathic arthritis: Tocilizumab, a humanized αIL-6R mAb, has been FDA approved for the treatment of several autoimmune diseases, including rheumatoid arthritis and systemic juvenile idiopathic arthritis, which demonstrates the feasibility and safety of inhibiting IL-6/STAT3 signaling systemically in human patients.